X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

By Gabby Migliara  |    August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...   Read More

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

By Gabby Migliara  |    August 12, 2020
According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of...   Read More

Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines

By Gabby Migliara  |    August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...   Read More

Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

By Katie Koziara  |    August 5, 2020
Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The report highlights...   Read More

New data show commercially insured patients face increasingly high cost sharing for brand medicines

By Gabby Migliara  |    July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...   Read More

Payers subject 80% of new RA and MS patients to utilization management restrictions

By Gabby Migliara  |    July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...   Read More

ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access

By Gabby Migliara  |    June 1, 2020
The two largest pharmacy benefit managers (PBMs), CVS Caremark and Express Scripts, have once again increased the number of medicines on their standard formulary exclusion lists. Medicines...   Read More

New rule makes it harder for patients to lower their out-of-pocket costs

By Holly Campbell  |    May 20, 2020
In the midst of increased financial insecurity for Americans due to the COVID-19 pandemic, it is shocking the Administration finalized a policy change in the 2021 Notice of Benefit and Payment...   Read More

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

By Holly Campbell  |    March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt  patients’ ability...   Read More

Fact Check: HCCI analysis overstates medicine spending and prices

By Katie Koziara  |    February 19, 2020
A recent analysis from the Health Care Cost Institute (HCCI) on health care spending overestimates medicine spending and pricing and mischaracterizes the true drivers of health care spending in...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates